Trophic Solutions

Trophic Solutions is a pre-clinical stage biotechnology company focused on developing neuroprotective therapies for ocular diseases, particularly glaucoma. Spun out of the Vanderbilt Eye Institute, the company's technology is based on the research of Dr. David Calkins into the role of neurotrophic factors in neuronal survival. Trophic Solutions is developing gene therapy and protein-based approaches to deliver factors like erythropoietin (EPO) and brain-derived neurotrophic factor (BDNF) directly to the retina. By enhancing the resilience of retinal ganglion cells, the company aims to prevent the vision loss associated with neurodegeneration, offering a potential complement to traditional intraocular pressure-lowering treatments.